Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US

被引:15
|
作者
Shah, Drishti [1 ]
Allen, Lindsay [2 ]
Zheng, Wanhong [3 ]
Madhavan, Suresh S. [1 ,4 ]
Wei, Wenhui [1 ,5 ]
LeMasters, Traci J. [1 ]
Sambamoorthi, Usha [1 ,4 ]
机构
[1] West Virginia Univ, Sch Pharm, Dept Pharmaceut Syst & Policy, POB 9510, Morgantown, WV 26506 USA
[2] West Virginia Univ, Sch Publ Hlth, Hlth Policy Management & Leadership Dept, Morgantown, WV 26506 USA
[3] West Virginia Univ, Dept Behav Med & Psychiat, Morgantown, WV 26506 USA
[4] Univ North Texas, Hlth Sci Ctr, Coll Pharm, Dept Pharmacotherapy, Ft Worth, TX USA
[5] Regeneron Pharmaceut, Tarrytown, NY USA
关键词
HEALTH-CARE EXPENDITURES; ANTIDEPRESSANT TREATMENT; TREATMENT RESPONSE; OUTCOMES; IMPACT; COSTS; POLYPHARMACY; PREVALENCE; DISABILITY; RISK;
D O I
10.1007/s40273-021-01029-2
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective Major depressive disorder (MDD) and chronic non-cancer pain conditions (CNPC) often co-occur and exacerbate one another. Treatment-resistant depression (TRD) in adults with CNPC can amplify the economic burden. This study examined the impact of TRD on direct total and MDD-related healthcare resource utilization (HRU) and costs among commercially insured patients with CNPC and MDD in the US. Methods The retrospective longitudinal cohort study employed a claims-based algorithm to identify adults with TRD from a US claims database (January 2007 to June 2017). Costs (2018 US$) and HRU were compared between patients with and without TRD over a 12-month period after TRD/non-TRD index date. Counterfactual recycled predictions from generalized linear models were used to examine associations between TRD and annual HRU and costs. Post-regression linear decomposition identified differences in patient-level factors between TRD and non-TRD groups that contributed to the excess economic burden of TRD. Results Of the 21,180 adults with CNPC and MDD, 10.1% were identified as having TRD. TRD patients had significantly higher HRU, translating into higher average total costs (US$21,015(TRD) vs US$14,712(No TRD)) and MDD-related costs (US$1201(TRD) vs US$471(No TRD)) compared with non-TRD patients (all p < 0.001). Prescription drug costs accounted for 37.6% and inpatient services for 30.7% of the excess total healthcare costs among TRD patients. TRD patients had a significantly higher number of inpatient (incidence rate ratio [IRR] 1.30, 95% CI 1.14-1.47) and emergency room visits (IRR 1.21, 95% CI 1.10-1.34) than non-TRD patients. Overall, 46% of the excess total costs were explained by differences in patient-level characteristics such as polypharmacy, number of CNPC, anxiety, sleep, and substance use disorders between the TRD and non-TRD groups. Conclusion TRD poses a substantial direct economic burden for adults with CNPC and MDD. Excess healthcare costs may potentially be reduced by providing timely interventions for several modifiable risk factors.
引用
收藏
页码:639 / 651
页数:13
相关论文
共 50 条
  • [21] Differential clinical and neurocognitive characteristics between patients with major depressive disorder and treatment-resistant depression
    Serafini, G.
    Giacomini, G.
    Porcelli, C.
    Zanaboni, S.
    Pompili, M.
    Amore, M.
    EUROPEAN PSYCHIATRY, 2019, 56 : S91 - S91
  • [22] THE ECONOMIC BURDEN AMONG PATIENTS WITH TREATMENT RESISTANT DEPRESSION IN US CLAIMS DATA
    Zhang, L.
    Li, G.
    Wang, G.
    Zhang, Q.
    DiBernardo, A.
    Lee, K.
    Benson, C.
    Reutfors, J.
    VALUE IN HEALTH, 2018, 21 : S183 - S183
  • [23] Depression Among Non-Cancer Chronic Pain Patients at a Tertiary Hospital in Malaysia
    Rajesh, K. M.
    Kumaravadivel, T. D.
    IIUM MEDICAL JOURNAL MALAYSIA, 2021, 20 (02): : 113 - 118
  • [24] Health-care utilisation and associated economic burden in major depressive disorder and treatment-resistant depression in a longitudinal population-based cohort study of 110.000 patients
    Pappa, Sofia
    Shah, Moulesh
    Young, Sophie
    Anwar, Tazneem
    Ming, Timothy
    JOURNAL OF PSYCHIATRIC RESEARCH, 2024, 180 : 511 - 518
  • [25] US NATIONAL PAYERS ANALYSIS OF THE INCREMENTAL HEALTHCARE BURDEN AMONG PATIENTS WITH TREATMENT-RESISTANT DEPRESSION
    Shrestha, A.
    Goutam, P.
    Roach, M.
    Everson, K.
    Sison, S.
    Joshi, K.
    Sheehan, J. J.
    Heerlein, K.
    Jena, A. B.
    VALUE IN HEALTH, 2019, 22 : S37 - S37
  • [26] Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone
    Kern, David M. M.
    Canuso, Carla M. M.
    Daly, Ella
    Johnson, Jonathan C. C.
    Fu, Dong Jing
    Doherty, Teodora
    Blauer-Peterson, Cori
    Cepeda, M. Soledad
    BRAIN AND BEHAVIOR, 2023,
  • [27] Treatment-resistant depression and risks of suicide and natural mortality in Taiwanese elderly patients with major depressive disorder
    Cheng, Chih-Ming
    Liu, Mu-N
    Tsai, Chia-Fen
    Tsai, Shih-Jen
    Chen, Mu-Hong
    INTERNATIONAL PSYCHOGERIATRICS, 2024, 36 : 95 - 95
  • [28] Work loss and healthcare utilization among US employees with chronic non-cancer pain
    Pizzi, LT
    Carter, CT
    Johnson, NE
    Howell, JB
    Vallow, SM
    Frank, ED
    VALUE IN HEALTH, 2003, 6 (03) : 189 - 190
  • [29] Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States
    Zhu, Ling
    Ferries, Erin
    Suthoff, Ellison
    Namjoshi, Madhav
    Bera, Rimal
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (11):
  • [30] PREDICTORS OF ALL-CAUSE HEALTHCARE PAYMENTS AMONG PATIENTS WITH TREATMENT-RESISTANT MAJOR DEPRESSIVE DISORDER
    Sussman, M.
    O'Sullivan, A.
    Shah, A.
    Menzin, J.
    Olfson, M.
    VALUE IN HEALTH, 2018, 21 : S183 - S183